|D003141||Communicable Diseases NIH||0.08|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The purpose of this study is to investigate the use of home pulse oximetry monitoring in patients with COVID-19 to trend disease progression and identify need for hospitalization.
Description: The primary outcome is the relative risk of hospitalization in COVID-19 patients with resting home pulse oximeter SpO2 below 92%.Measure: Hospitalization in COVID-19 patients with low home SpO2 Time: 7 days after enrollment
Description: The purpose of this outcome is to determine if home pulse oximetry readings abruptly drop, gradually decline, or stay level in patients with COVID-19Measure: Trend in resting home pulse oximetry readings Time: 7 days after enrollment
Description: This will evaluate if there is a correlation between the time of day with SpO2 readings below 92 percent in patients with suspected COVID-19.Measure: Timing of SpO2 <92% Time: 7 days after enrollment
Description: The goal of this outcome is to see if patients enrolled in the study are reassured by use of home pulse oximeter monitoring and if this device prevents subsequent ED visits by patientsMeasure: Home pulse oximeter use effect on subsequent ED visits Time: 7 days after enrollment
Description: To see if patients who return to the ED and end up hospitalized did so for incidental finding of low home pulse oximetry or if it was for worsening symptomsMeasure: Reason for return to the Emergency Department Time: 7 days after enrollment
Description: The study will assess development of morbidity defined as intensive care unit admission, acute respiratory distress syndrome, and/or septic shock in patients with SpO2 <92%Measure: Hospitalization outcome - morbidity Time: Up to 21 days after enrollment
Description: The study will assess mortality defined as death after admission to the hospital in patients with SpO2 <92%Measure: Hospitalization outcome - mortality Time: Up to 21 days after enrollment
Description: The study will measure median length of stay in patients with COVID-19 that are hospitalized on subsequent return to the ED.Measure: Median Length of Stay Time: Up to 21 days after enrollment
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports